Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.
Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications.
Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
February 2022—Roche announced that the FDA has granted emergency use authorization for its COVID-19 At-Home Test. The test uses an anterior nasal swab sample that can be self-collected and self-tested by people ages 14 years and older and by an adult for children ages two to 13 years old. Results are available in as few as 20 minutes for SARS-CoV-2 and all known variants of concern, including omicron.
January 2022—Siemens Healthineers announced that the company’s SARS-CoV-2 tests are designed to detect the omicron variant. The company evaluated the potential impact of the variant on the Clinitest Rapid COVID-19 antigen test; the FTD SARS-CoV-2 assay, a PCR test; and the Atellica IM/Advia Centaur SARS-CoV-2 antigen assay (CoV2Ag). To assess the potential impact of the Clinitest rapid test and the CoV2Ag assay, Siemens’ R&D team analyzed the sequence data of the omicron variant nucleocapsid protein, which demonstrated greater than 98 percent sequence homology of the nucleocapsid protein to other SARS-CoV-2 variants. The Clinitest Rapid COVID-19 Antigen Self-Test has a sensitivity of 97.25 percent and a specificity of 100 percent compared with a PCR, or nucleic acid-detection method, and provides results in 15 minutes.
January 2022—Bio-Rad Laboratories launched its Exact Diagnostics SARS-CoV-2 S Gene Delta-Kappa Variants Control for research testing. The control includes lineages B.1.617.1, B.1.617.2 (AY sublineages), and B.1.617.3. The product is an addition to the company’s SARS-CoV-2 S gene variants controls alpha, beta, epsilon, and gamma, which were released in August.
January 2022—Streck announced the availability of its MDx-Chex for BCID2 quality control, designed to meet the standards for verifying the performance of sample-to-result molecular tests for sepsis.
January 2022—LumiraDx announced a partnership with digital health nonprofit Audere to offer a COVID-19 nasal specimen collection kit that has been authorized for use with the LumiraDx SARS-CoV-2 RNA Star Complete assay to process self-collected samples. SARS-CoV-2 RNA Star Complete has received FDA emergency use authorization for use by authorized laboratories. Laboratories using SARS-CoV-2 RNA Star Complete will be able to integrate Audere’s HealthPulse@home into their systems.
January 2022—Co-Diagnostics has entered into definitive agreements with Idaho Molecular and Advanced Conceptions in which both companies will become wholly owned subsidiaries of Co-Dx. Salt Lake City–based Co-Dx has been working with Idaho Molecular and Advanced Conceptions on the development of Co-Dx’s at-home, point-of-care diagnostic device. The transactions will provide Co-Dx with existing and future assets and intellectual property related to the platform.
January 2022—Death investigators are tasked with the responsibility of providing irrefutable and accurate determinations in the cause and manner of death in a timely fashion for ongoing investigations. Outcomes of any death may be revealed by the specimens submitted for toxicology analysis. The conundrum of ample opinions is that there is no “one size fits all” when selecting appropriate specimens. Human nature tends to rely on traditional approaches for the collection, processing, and reporting of results because it’s easier to stay status quo. However, with drug overdose deaths increasing, reports are further delayed, causing an influx of backlogged cases. To assist with these issues, our laboratory developed an economical, time-efficient, safe, and less-invasive collection method that delivers real-time results within 24 to 48 hours, accelerating the autopsy process and the ability to close cases expeditiously.
January 2022—Roche launched its Cobas 5800 system in countries accepting the CE mark. The real-time PCR molecular testing solution is built to offer a fully automated workflow that encompasses sample supply, transfer and preparation, amplification and detection, result calculation, and delivery to the laboratory information system. The single module enables a walkaway time of up to eight hours.
January 2022—Seegene unveiled the Novaplex SARS-CoV-2 Variants VII assay for research use only. The assay identifies positive COVID-19 cases and distinguishes between alpha, beta, gamma, delta, and omicron and its stealth version. The RT-PCR test targets five analytes including the RdRP gene and three omicron S-gene mutations, E484A, N501Y, HV69/70 deletion. It also targets endogenous internal controls, which serve as a control to verify specimen validity.
December 2021—Hardy Diagnostics has released its HardyChrom Candida plus auris, a chromogenic media recommended for the selective isolation and differential identification of Candida species. This medium allows for the identification of C. albicans, C. tropicalis, and C. krusei, and the presumptive identification of C. glabrata.
